Dr June Raine has been the director of Vigilance and Risk Management of Medicines (VRMM) division since 2006. Photo Courtesy: MHRA

Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Dr June Raine as the new interim chief executive.

Raine, who has been the director of Vigilance and Risk Management of Medicines division at the agency since 2006, will take up her new position on September 20.

“Dr Raine has spent her professional career in the Agency and its predecessor bodies. She is recognised as one of the leading experts in the field of medicines safety, playing a central role in the Agency’s work. I am delighted that she has agreed to act as interim chief executive of the Agency for the coming months,” said MHRA chairman Sir Michael Rawlins.

Qualified in medicine from Oxford University, Raine undertook postgraduate research leading to MSc Pharmacology. She joined the health department’s medicines division in 1985 and moved to the MHRA when it was formed in 2003.

Raine has also chaired the European Pharmacovigilance Risk Assessment Committee on behalf of the European Medicines Agency for six years.

“I am proud to be asked to lead the Agency at this time and am looking forward to working with colleagues across the health and care sector to protect and promote public health, in the UK and internationally,” Dr Raine said.

Raine replaces Dr Ian Hudson who has stepped down after serving six years in the role.

“It has been a pleasure and privilege to have worked with so many able and committed people over the past 18 years. Our Agency makes a real difference to the health of millions of people in the UK, Europe and beyond, and it has been an honour to make a contribution to this work,” Hudson said.